0001213900-21-063813.txt : 20211207 0001213900-21-063813.hdr.sgml : 20211207 20211207094552 ACCESSION NUMBER: 0001213900-21-063813 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20211207 DATE AS OF CHANGE: 20211207 EFFECTIVENESS DATE: 20211207 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Saliogen Therapeutics, Inc. CENTRAL INDEX KEY: 0001845309 IRS NUMBER: 844170116 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-423901 FILM NUMBER: 211474877 BUSINESS ADDRESS: STREET 1: 245 FIRST STREET STREET 2: 18TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: (857) 990-2200 MAIL ADDRESS: STREET 1: 245 FIRST STREET STREET 2: 18TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 D 1 primary_doc.xml X0708 D LIVE 0001845309 Saliogen Therapeutics, Inc. 245 FIRST STREET 18TH FLOOR CAMBRIDGE MA MASSACHUSETTS 02142 (857) 990-2200 DELAWARE None None Corporation true 2020 Raymond Tabibiazar 245 First Street 18th Floor Cambridge MA MASSACHUSETTS 02142 Executive Officer Director Joseph Higgins 245 First Street 18th Floor Cambridge MA MASSACHUSETTS 02142 Executive Officer Director Sukumar Nagendran 245 First Street 18th Floor Cambridge MA MASSACHUSETTS 02142 Director While no offering proceeds are set aside for payments to the named officers or directors, it is possible that some proceeds to be used as working capital will be used indirectly for paying salaries to employees including executive officers. Sean Stalfort 245 First Street 18th Floor Cambridge MA MASSACHUSETTS 02142 Director Craig Gordon 245 First Street 18th Floor Cambridge MA MASSACHUSETTS 02142 Director Biotechnology Decline to Disclose 06b false 2021-11-24 false true false 0 125000000 74099666 50900334 false 11 0 0 0 While no offering proceeds are set aside for payments to the named officers or directors, it is possible that some proceeds to be used as working capital will be used indirectly for paying salaries to employees including executive officers. false Saliogen Therapeutics, Inc. /s/ Raymond Tabibiazar Raymond Tabibiazar Chief Executive Officer 2021-12-07